Google
NCEL — NEWCELX LTD. (Healthcare >> Biotechnology)
NCEL FAQ
What is NCEL's P/E ratio?
NEWCELX LTD. (NCEL) currently trades at a P/E ratio of 282.49.
What is NCEL's ROE?
NEWCELX LTD. reports a Return on Equity (ROE) of -114.48%.
What is NCEL's dividend yield?
NEWCELX LTD. offers a dividend yield of 0.00%.
What is NCEL's Deepscope Quality Score?
Deepscope rates NCEL's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NCEL?
Deepscope's AI Timing Score for NCEL is 67 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does NCEL belong to?
NEWCELX LTD. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 3.24
Price
0.31
(10.58%)
Day Change
|
|
|---|
NCEL, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.24 |
| PBV / Sector |
2.14 / 4.75
|
| Earning Per Share | -1.73 |
| PE / Sector |
282.49 / 17.65
|
| PEG or PE/Growth / Sector |
2.35 / 0.52
|
| Average 1M Daily Value |
0.21 M
GREAT
|
| Average 1W Daily Value |
0.06 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-09 09:39:44 |
| Symbol | NCEL |
| Name | NEWCELX LTD. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 5.38 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 15.54 / 9,000.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Hohstrasse 1, Kloten, Switzerland, 8302
Phone: 41 44 512 21 50
Website: https://newcelx.com
Sector: Healthcare >> Biotechnology
Description: NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
